Signet ring cell carcinoma of breast: Single center experience.
Authors: Serkan Akin, Omer Diker, Neyran Kertmen, Ozturk Ates, Omer Dizdar, Suayib Yalcin, Kadri Altundag
Journal: Journal of Clinical Oncology (2015)

Article Tools Breast Cancer—HER2/ER Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/jco.2015.33.15_suppl.e11513 Journal of Clinical Oncology - published online before print May 20, 2015 Signet ring cell carcinoma of breast: Single center experience. Serkan AkinxSerkan AkinSearch for articles by this author , Omer DikerxOmer DikerSearch for articles by this author , Neyran KertmenxNeyran KertmenSearch for articles by this author , Ozturk AtesxOzturk AtesSearch for articles by this author , Omer DizdarxOmer DizdarSearch for articles by this author , Suayib YalcinxSuayib YalcinSearch for articles by this author , Kadri AltundagxKadri AltundagSearch for articles by this author Show More Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey Abstract Disclosures https://doi.org/10.1200/jco.2015.33.15_suppl.e11513 Abstract Abstract e11513 Background: Signet ring cell carcinoma (SRCC) of breast is a rare subtype with aggressive clinical course. It is classified under "mucin-producing carcinomas" in 2003 WHO classification. Here we analyzed clinical and pathological features and outcomes of our patients with SRCC of breast. Methods: We investigated retrospectively medical charts of 3587 patients with breast cancer in Hacettepe University Cancer Institute between 2007-2013. Patient demographics, pathology reports were assessed along with clinical outcomes. Results: Twenty five patients with SRCC were identified (1%). Demographic and clinical features were presented in Table 1. Oral contraceptive and hormone replacement treatment had been used in 8(32%) and 6(24%) patients respectively. Tumors were mostly grade 2, ER positive and her2 negative. In patients with mixed histology, co-existed histology was invasive ductal carcinoma in 9 patients and invasive lobular carcinoma in 6 patients. Median follow up was 27 months. Seven patients had recurrence. Most common site of distant relapses were bone, liver and ovaries (3, 2 and 2 patients respectively). Median OS was 71 months (95% CI: 37-105 mos). Median DFS in patients with localized disease was 42 months (95%CI: 1,5-83 mos). Conclusions: In this study, the prevalence of SRCC was found 0,7 %, which is lower than that reported in the literature. Pathological features including tumor grade, hormone receptor and her2 positivity are similar with ductal carcinoma. Histology was mostly mixed, with ductal carcinoma being the most common accompanying subtype. Ovarian metastases was found in 2 of 7 distant failures. SRC histology may have a predilection for ovarian metastases. Clinical characteristics in patients with SRCC (n = 25). Median age 53 (min: 31, max: 70) Menopause Pre- 12 (48%) Post- 13 (52%) Body mass index 27.9 ± 4.6 (min: 20.7, max: 40) Histology Pure 6 (24%) Mixed 19 (76%) Lymphovascular invasion 10 (40%) Grade 2 17 (68%) 3 8(32%) Stage(T) T1 5 (20%) T2 11 (44%) T3 5 (20%) T4 3 (12%) Stage (N) N0 7 (28%) N1 6 (24%) N2 5 (20%) N3 7 (28%) Stage(TNM) 1 2 (8%) 2 7 (28%) 3 12 (48%) 4 4 (16%) ER 19 (76%) PR 14 (56%) Her2 7 (28%) Radiotherapy 22 (88%) Hormonotherapy 17 (68%) Chemotherapy (Adjuvant/neoadjuvant) 19 (76%) © 2015 by American Society of Clinical Oncology